Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%

Stock Information for PLUS THERAPEUTICS Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About PLUS THERAPEUTICS Inc.

Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ(TM) Clinical Program and CNSide® Commercial Rollout
Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ(TM)
Plus Therapeutics Provides Business Update on REYOBIQ(TM) Clinical Program and U.S. CNSide® Commercialization
Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET
Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering
Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ(TM) for Leptomeningeal Metastases
Plus Therapeutics Expands CNSide Assay Platform to State of California
Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.